# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Oppenheimer analyst Leland Gershell maintains UroGen Pharma (NASDAQ:URGN) with a Outperform and lowers the price target from...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $54 price...
12-month duration of response data from ENVISION study of UGN-102 to be discussed during company sponsored virtual event on Jun...
UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(0.97) per share which missed the analyst consensus estimate of $(0.8...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $54 price...
New and Recurrent Patients Treated with UGN-102 Achieved Similar Durability of Response Rates (DOR) at 12 months UroGen Pha...
There Were No Differences in RFS Regarding Usage for Chemoablation or Post-Endoscopic Ablation, Tumor Size, Multifocality, or...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $54 price...
UroGen plans to initiate a Phase 3 study to explore the safety and efficacy of UGN-103 in 2024Anticipated advantages include a ...